Adherence enhancing interventions for oral anticancer agents: A systematic review

Mathes, Tim; Antoine, Sunya-Lee; Pieper, Dawid; Eikermann, Michaela

doi:10.1016/j.ctrv.2013.07.004

Cited by 67 publications

(88 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further work is clearly needed using methodologically rigorous, prospective randomized designs in larger samples of patients that assess not only adherence with multiple methods but also clinically meaningful outcomes, such as quality of life, symptoms, and adverse effects of therapy, as well as cancer progression and survival. In the other systematic review of interventions to promote adherence to oral antineoplastic that has been published to date, the investigators drew similar conclusions [68].…”

Section: Overview Of Findingsmentioning

confidence: 76%

“…Although several reviews of adherence to oral antineoplastic therapies have been published [8,12,69,70], only a few were based on the systematic reporting criteria per PRISMA guidelines [10,11,68]. Furthermore, we examined observational, retrospective database, cohort, and randomized intervention studies to describe not only rates and correlates of adherence but also empirical efforts to date to improve proper administration of these oral agents.…”

Section: Overview Of Findingsmentioning

confidence: 99%

See 1 more Smart Citation

A Systematic Review of Adherence to Oral Antineoplastic Therapies

et al. 2016

View full text Add to dashboard Cite

Background. Oral antineoplastic therapies not only improve survival but also reduce the burden of care for patients. Yet patients and clinicians face new challenges in managing adherence to these oral therapies. We conducted a systematic literature review to assess rates and correlates of adherence to oral antineoplastic therapies and interventions aimed at improving adherence. Methods. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted a comprehensive literature search of the Ovid MEDLINE database from January 1, 2003 to June 30, 2015, using relevant terminology for oral antineoplastic agents. We included observational, database, and intervention studies. At least two researchers evaluated each paper to ensure accuracy of results and determine risk of bias. Results. We identified 927 records from the search and screened 214 abstracts. After conducting a full-text review of 167

show abstract

Section: Overview Of Findingsmentioning

confidence: 76%

Section: Overview Of Findingsmentioning

confidence: 99%

A Systematic Review of Adherence to Oral Antineoplastic Therapies

et al. 2016

View full text Add to dashboard Cite

show abstract

“…An important finding was also that treatment nonadherence was distributed over time. We think that educational support of patients has to be repeated, even in patients supposedly adherent and taking their medication for a long time [16]. …”

Section: Discussionmentioning

confidence: 99%

Adherence and Patients' Attitudes to Oral Anticancer Drugs: A Prospective Series of 201 Patients Focusing on Targeted Therapies

et al. 2014

View full text Add to dashboard Cite

Objectives: Patient adherence is a challenge in oncology and hematology practice. Hormone therapy data in breast cancer suggest insufficient adherence and poor persistence. Limited data are available for targeted therapies (TT) including tyrosine kinase and mammalian target of rapamycin inhibitors. Methods: We performed a prospective survey using a 15-item questionnaire in patients with solid tumors and hematologic malignancies receiving oral anticancer therapy. Treatment duration, setting (adjuvant vs. metastatic), cancer type, age, and comedication were recorded. Results: 201 patients (median age 65.5 years) participated, 102 with TT and 99 with hormone therapy or chemotherapy (HC). The median time of drug intake was 11.0 months. Written information was more frequently given to TT patients (68.6 vs. 23.2%, p < 0.0001). TT and HC patients showed equal adherence to therapy (72.5 vs. 69.6%, p = n.s.) despite TT patients experiencing more side effects (p < 0.0001) and taking more concomitant oral medication (p = 0.0042). Forgotten doses were the leading cause of nonadherence in HC patients (83%, as compared to 54% in the TT group), whereas dose reduction by the patient was higher in the TT group (32 vs. 17%). Conclusions: Despite advances in providing information to patients leading to better adherence among TT patients, efforts towards better patient education are warranted including dedicated staff for monitoring outpatient anticancer oral therapy.

show abstract

“…1 This low medication adherence is problematic because it is associated with poorer prognosis for many common conditions. 2 Evidence has demonstrated that non-White patients are less likely to adhere to medication regimens than White patients, 3,4 suggesting that medication adherence may be an important lever for targeting racial disparities in health care outcomes. Medication adherence has become a particularly important issue in cancer care because the use of oral anticancer drugs in clinical practice has increased.…”

mentioning

confidence: 99%

Racial/Ethnic and Socioeconomic Disparities in Endocrine Therapy Adherence in Breast Cancer: A Systematic Review

2015

View full text Add to dashboard Cite

We examined the current literature to understand factors that influence endocrine therapy (ET) adherence among racial/ethnic and socioeconomic subpopulations of breast cancer patients. We searched PubMed and PsycINFO databases for studies from January 1, 1978, to June 20, 2014, and January 1, 1991, to June 20, 2014, respectively, and hand-searched articles from relevant literature reviews. We abstracted and synthesized results within a social ecological framework. Fourteen articles met all inclusion criteria. The majority of included articles reported significant underuse of ET among minority and low-income women. Modifiable intrapersonal, interpersonal, and community-level factors are associated with ET use, and these factors vary across subgroups. Both race/ethnicity and socioeconomic status are associated with ET use in most settings. Variation in factors associated with ET use across subgroups indicates the need for more nuanced research and targeted interventions among breast cancer patients.

show abstract

Adherence enhancing interventions for oral anticancer agents: A systematic review

Cited by 67 publications

References 18 publications

A Systematic Review of Adherence to Oral Antineoplastic Therapies

A Systematic Review of Adherence to Oral Antineoplastic Therapies

Adherence and Patients' Attitudes to Oral Anticancer Drugs: A Prospective Series of 201 Patients Focusing on Targeted Therapies

Racial/Ethnic and Socioeconomic Disparities in Endocrine Therapy Adherence in Breast Cancer: A Systematic Review

Contact Info

Product

Resources

About